Intensified chemotherapy with stem-cell rescue in germ-cell tumors

Annals of Oncology

Volumn 23, Issue 4, 2012, Pages 815-822

  Simonelli, M ^a   Rosti, G ^b   Banna, G L ^c   Pedrazzoli, P ^d  

^a HUMANITAS CLINICAL AND RESEARCH CENTER   (Italy)

^b OSPEDALE CA FONCELLO   (Italy)

^c CANNIZZARO HOSPITAL   (Italy)

^d FONDAZIONE IRCCS POLICLINICO SAN MATTEO   (Italy)

Author keywords

Autologous stem cell transplantation; Germ cell tumors; High dose chemotherapy

Indexed keywords

ANTINEOPLASTIC AGENT; BLEOMYCIN; CARBOPLATIN; CISPLATIN; CYCLOPHOSPHAMIDE; DACTINOMYCIN; EPIRUBICIN; ETOPOSIDE; IFOSFAMIDE; PACLITAXEL; THIOTEPA; VINBLASTINE;

ADVANCED CANCER; AUTOLOGOUS STEM CELL TRANSPLANTATION; CANCER CHEMOTHERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER PROGNOSIS; CANCER RELAPSE; CANCER RESEARCH; CANCER RISK; CANCER SURVIVAL; CLINICAL EFFECTIVENESS; CLINICAL EVALUATION; CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DRUG DOSE ESCALATION; DRUG DOSE REDUCTION; DRUG EFFECT; DRUG EFFICACY; DRUG MEGADOSE; DRUG TREATMENT FAILURE; GERM CELL TUMOR; HUMAN; MEDIASTINUM TUMOR; MULTIPLE CYCLE TREATMENT; OUTCOME ASSESSMENT; PRIMARY HEALTH CARE; PRIMARY TUMOR; PRIORITY JOURNAL; RECURRENT CANCER; RETROSPECTIVE STUDY; REVIEW; RISK ASSESSMENT; TREATMENT DURATION; TREATMENT PLANNING;

EID: 84859492667     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdr403     Document Type: Review

References (56)

1. Einhorn LH. Testicular cancer: an oncological success story. Clin Cancer Res 1997; 3: 2630-2632.
2. Bosl GJ, Motzer RJ. Testicular germ-cell cancer. N Engl J Med 1997; 337: 242-253.
3. Williams SD, Birch R, Einhorn LH et al. Treatment of disseminated germ-cell tumors with cisplatin, bleomycin, and either vinblastine or etoposide. N Engl J Med 1987; 316: 1435-1440.
4. Loehrer PJ Sr, Gonin R, Nichols CR et al. Vinblastine plus ifosfamide plus cisplatin as initial salvage therapy in recurrent germ cell tumor. J Clin Oncol 1998; 16: 2500-2504.
5. McCaffrey JA, Mazumdar M, Bajorin DF et al. Ifosfamide and cisplatin-containing chemotherapy as first-line salvage therapy in germ-cell tumors: response and survival. J Clin Oncol 1997; 15: 2559-2563.
6. Skipper HE. Dose intensity versus total dose of chemotherapy: an experimental basis. In De Vita VT, Hellman S, Rosemberg SA (eds). Important Advances in Oncology. Philadelphia, PA: Lippincott 1990; 43-64.
7. Siena S, Bregni M, Brando B et al. Circulation of CD34+ hematopoietic stem cells in the peripheral blood of high-dose cyclophosphamide-treated patients: enhancement by intravenous recombinant human granulocyte-macrophage colony-stimulating factor. Blood 1989; 74: 1905-1914.
8. Schmitz N, Linch DC, Dreger P et al. Randomized trial of filgrastim-mobilized peripheral blood progenitor cell transplantation versus autologous bone-marrow transplantation in lymphoma patients. Lancet 1996; 347: 353-357.
9. Siena S, Schiavo R, Pedrazzoli P, Carlo-Stella C. Therapeutic relevance of CD34 cell dose in blood cell transplantation for cancer therapy. J Clin Oncol 2000; 18: 1360-1377.
10. Pedrazzoli P, Rosti G, Secondino S et al. High-dose chemotherapy with autologous hematopoietic stem cell support for solid tumors in adults. Semin Hematol 2007; 44: 286-295.
11. International Germ-Cell Cancer Collaborative Group. International Germ Cell Consensus Classification: a prognostic factor-based staging system for metastatic germ cell cancers. International Germ Cell Cancer Collaborative Group. J Clin Oncol 1997; 15: 594-603.
12. Motzer RJ, Mazumdar M, Gulati SC et al. Phase II trial of high-dose carboplatin and etoposide with autologous bone marrow transplantation in first-line therapy for patients with poor-risk germ cell tumors. J Natl Cancer Inst 1993; 85: 1828-1835.
13. Motzer RJ, Mazumdar M, Bajorin DF et al. High-dose carboplatin, etoposide, and cyclophosphamide with autologous bone marrow transplantation in first-line therapy for patients with poor-risk germ cell tumors. J Clin Oncol 1997; 15: 2546-2552.
14. Bokemeyer C, Kollmannsberger C, Meisner C et al. First-line high-dose chemotherapy compared with standard-dose PEB/VIP chemotherapy in patients with advanced germ cell tumors: a multivariate and matched-pair analysis. J Clin Oncol 1999; 17: 3450-3456.
15. Birch R, Williams S, Cone A et al. Prognostic factors for favourable outcome in disseminated germ cell tumors. J Clin Oncol 1986; 4: 400-407.
16. Schmoll HJ, Kollmannsberger C, Metzner B et al. Long-term results of first-line sequential high dose VIP chemotherapy plus autologous stem cell support for patients with advanced metastatic germ cell cancer: an extended phase I/II study of the German Testicular Cancer Study Group. J Clin Oncol 2003; 21: 4083-4091.
17. Motzer RJ, Chou TC, Schwartz L et al. Paclitaxel in germ cell cancer. Semin Oncol 1995; 22: 12-15.
18. Kondagunta GV, Bacik J, Sheinfeld J et al. Paclitaxel plus ifosfamide followed by high-dose carboplatin plus etoposide in previously treated germ cell tumors. J Clin Oncol 2007; 25: 85-90.
19. Motzer RJ, Mazumdar M, Sheinfeld J et al. Sequential dose-intensive paclitaxel, ifosfamide, carboplatin, and etoposide salvage therapy for germ cell tumor patients. J Clin Oncol 2000; 8: 1173-1180.
20. Hartmann JT, Gauler T, Metzner B et al. Phase I/II study of sequential doseintensified ifosfamide, cisplatin, and etoposide plus paclitaxel as induction chemotherapy for poor prognosis germ cell tumors by the German Testicular Cancer Study Group. J Clin Oncol 2007; 25: 5742-5747.
21. Motzer RJ, Nichols CJ, Margolin KA et al. Phase III randomized trial of conventional-dose chemotherapy and autologous hematopoietic stem-cell rescue as first-line treatment for patients with poor-prognosis metastatic germ cell tumors. J Clin Oncol 2007; 25: 247-256.
22. Di Nicola M, Necchi A, Nicolai N et al. High-dose sequential chemotherapy versus conventional-dose chemotherapy as first-line treatment for advanced poor prognosis germ-cell tumors: a multicenter phase III Italian trial. Ann Oncol 2009; 20 (Suppl 8): viii3-viii4.
23. Daugaard G, Skoneczna IA, Aass N et al. A randomized phase III study comparing standard dose BEP with sequential high-dose cisplatin, etoposide, ifosfamide (VIP) plus stem cell support in males with poor prognosis germ cell cancer (GCC): an intergroup study of EORTC, GTCSG, and Grupo Germinal (EORTC 30974). Proc Am Soc Clin Oncol 2010; 28 (Suppl): 15s (Abstr 4512).
24. Kondagunta GV, Bacik J, Donadio A et al. Combination of paclitaxel, ifosfamide, and cisplatin is an effective second-line therapy for patients with relapsed testicular germ cell tumors. J Clin Oncol 2005; 23: 6549-6555.
25. Postmus PE, De Vries EG, De Vries-Hospars HG et al. Cyclophosphamide and VP16-213 with autologous bone marrow transplantation: a dose escalation study. Eur J Cancer Clin Oncol 1984; 20: 777-782.
26. Ghosn M, Droz JP, Theodore C et al. Salvage chemotherapy in refractory germ cell tumors with etoposide (VP-16) plus ifosfamide plus high-dose cisplatin. A VihP regimen. Cancer 1988; 62: 24-27.
27. Nichols CR, Tricot G, Williams SD et al. Dose-intensive chemotherapy in refractory germ cell cancer-a phase 1/2 trial of high-dose carboplatin and etoposide with autologous bone marrow transplantation. J Clin Oncol 1989; 7: 932-939.
28. Brown ER, Nichols CR, Kneebone P et al. Long-term outcome of patients with relapsed and refractory germ cell tumors treated with high-dose chemotherapy and autologous bone marrow rescue. Ann Intern Med 1992; 117: 124-128.
29. Motzer RJ, Gulati SC, Crown JP et al. High-dose chemotherapy with autologous bone marrow rescue for patients with refractory germ cell tumors. Early intervention is better tolerated. Cancer 1992; 69: 550-556.
30. Siegert W, Beyer J, Strohscheer I et al. High-dose treatment with carboplatin, etoposide, and ifosfamide followed by autologous stemcell transplantation in relapsed or refractory germ cell cancer: a phase I/II study. The German Testicular Cancer Cooperative Study Group. J Clin Oncol 1994; 12: 1223-1231.
31. Beyer J, Kramar A, Mandanas R et al. High-dose chemotherapy as salvage treatment in germ cell tumors: a multivariate analysis of prognostic variables. J Clin Oncol 1996; 14: 2638-2645.
32. Rick O, Bokemeyer C, Beyer J et al. Salvage treatment with paclitaxel, ifosfamide, and cisplatin plus high-dose carboplatin, etoposide, and thiotepa followed by autologous stem-cell rescue in patients with relapsed or refractory germ cell cancer. J Clin Oncol 2001; 19: 81-88.
33. Bhatia S, Abonour R, Porcu P et al. High dose chemotherapy as initial salvage chemotherapy in patients with relapsed testicular cancer. J Clin Oncol 2000; 18: 3346-3351.
34. Rodenhuis S, Westermann A, Holtkamps MJ et al. Feasibility of multiple courses of high dose cyclophosphamide, thiotepa and carboplatin for breast cancer or germ cell cancer. J Clin Oncol 1996; 14: 1473-1483.
35. Beyer J, Stenning S, Gerl A et al. High-dose versus conventional-dose chemotherapy as first-salvage treatment in patients with non-seminomatous germ-cell tumors: a matched-pair analysis. Ann Oncol 2002; 13: 599-605.
36. Einhorn LH, Williams SD, Chamness BA et al. High-dose chemotherapy and stem cell rescue for metastatic germ-cell tumors. N Engl J Med 2007; 357: 340-348.
37. Feldman DR, Sheinfeld J, Bajorin DF et al. TI-CE high-dose chemotherapy for patients with previously treated germ cell tumors: results and prognostic factor analysis. J Clin Oncol 2010; 28: 1706-1713.
38. Pico JL, Rosti G, Kamar A et al. A randomised trial of high-dose chemotherapy in the salvage treatment of patients failing first-line platinum chemotherapy for advanced germ cell tumours. Ann Oncol 2005; 16: 1152-1159.
39. Lorch A, Kollmannsberger C, Hartmann JT et al. Single versus sequential highdose chemotherapy in patients with relapsed or refractory germ-cell tumors: a prospective randomized multicentre trial of the German Testicular Cancer Study Group. J Clin Oncol 2007; 25: 2778-2784.
40. Lorch A, Kleinhans A, Kramar A et al. Superior survival after sequential high-dose chemotherapy (HDCT) as compared to single HDCT in patients with relapsed or refractory germ cell tumors (GCT): six-year long-term follow-up of a prospective, randomized phase II trial. Proc Am Soc Clin Oncol 2011; 29 (Suppl): 15 (Abstr 4507).
41. Norton L, Simon R. The Norton-Simon hypothesis revisited. Cancer Treat Rep 1986; 70: 163-169.
42. The International Prognostic Factors Study Group. Prognostic factors in patients with metastatic germ cell tumors who experienced treatment failure with cisplatin-based first-line chemotherapy. J Clin Oncol 2010; 28: 4906-4911.
43. Lorch A, Bascoul-Mollevi C, Kramar A et al. Conventional-dose versus high-dose chemotherapy as first salvage treatment in male patients with metastatic germ cell tumors: evidence from a large international database. J Clin Oncol 2011; 29 (16): 2178-2184.
44. Pedrazzoli P, De Giorgi U, Bregni M. High-dose chemotherapy (HDCT) and autologous stem cell transplantation in relapsed germ cell tumors: do we need a randomized study? Bone Marrow Transplant 2010; 45 (Suppl 2): S30.
45. Horwich A. Salvage therapy of germ cell tumors. Br J Cancer 1995; 71: 901-903.
46. Lotz JP, Bui B, Gomez F et al. Sequential high-dose chemotherapy protocol for relapsed poor prognosis germ cell tumors combining two mobilization and cytoreductive treatments followed by three high-dose chemotherapy regimens supported by autologous stem cell transplantation. Results of the phase II multicentric TAXIF trial. Ann Oncol 2005; 16: 411-418.
47. Vaena DA, Abonour R, Einhorn LH. Long-term survival after high-dose salvage chemotherapy for germ cell malignancies with adverse prognostic variables. J Clin Oncol 2003; 21: 4100-4104.
48. Lorch A, Neubauer A, Hackenthal M et al. High-dose chemotherapy (HDCT) as second-salvage treatment in patients with multiple relapsed or refractory germcell tumors. Ann Oncol 2010; 21: 820-825.
49. Schmoll HJ. Extragonadal germ cell tumors. Ann Oncol 2002; 13: 265-272.
50. Bokemeyer C, Nichols CR, Droz JP et al. Extragonadal germ cell tumors of the mediastinum and retroperitoneum: results from an international analysis. J Clin Oncol 2002; 20: 1864-1873.
51. Bokemeyer C, Schleucher N, Metzner B et al. First-line sequential high-dose VIP chemotherapy with autologous transplantation for patients with primary mediastinal nonseminomatous germ cell tumours: a prospective trial. Br J Cancer 2003; 89: 29-35.
52. Rosti G, De Giorgi U, Wandt H et al. First-line high-dose chemotherapy for patients with poor prognosis extragonadal germ cell tumors: the experience of the European Bone Marrow Transplantation (EBMT) Solid Tumors Working Party. Bone Marrow Transplant 2004; 34: 1033-1037.
53. Banna GL, De Giorgi U, Ferrari B et al. Is high-dose chemotherapy after primary chemotherapy a therapeutic option for patients with primary mediastinal nonseminomatous germ cell tumor? Biol Blood Marrow Transplant 2006; 12: 1085-1091.
54. Hartmann JT, Einhorn L, Nichols CR et al. Second line chemotherapy in patients with relapsed extragonadal nonseminomatous germ cell tumors: results of an international multicenter analysis. J Clin Oncol 2001; 19: 1641-1648.
55. De Giorgi U, Demirer T, Wandt H et al. Second-line high-dose chemotherapy in patients with mediastinal and retroperitoneal primary non-seminomatous germ cell tumors: the EBMT experience. Ann Oncol 2005; 16: 146-151.
56. Brave M, Farrell A, Ching Lin S et al. FDA review summary: Mozobil in combination with granulocyte colony-stimulating factor to mobilize hematopoietic stem cells to the peripheral blood for collection and subsequent autologous transplantation. Oncology 2010; 78: 282-288.